Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 331, Issue 4, pp 324–333 | Cite as

Binding of agonists and antagonists to β-adrenoceptors in rat vas deferens: relationship to functional response

  • John Marvin May
  • Peter W. Abel
  • Kenneth P. Minneman
Article

Summary

The properties of β-adrenoceptors in rat vas deferens were examined using radioligand binding assays of 125I-pindolol (125IPIN) and inhibition of electrically-evoked contractions of vas deferens in vitro. 125IPIN labelled a single class of high affinity binding sites with apparently mass action kinetics in membrane preparations of vas deferens with properties consistent with an essentially homogeneous population of β2-adrenoceptors. Isoprenaline inhibited electrically evoked (60 V, 1.0 ms, 0.1 Hz) contractions of vas deferens with an EC50 of 18.0±2.1 nM. KB values for antagonists in competitively antagonizing this response correlated well (r2=0.99) with the KD values for inhibition of 125IPIN binding. Inhibition of 125IPIN binding by isoprenaline, adrenaline, noradrenaline and salbutamol was determined under conditions designed to produce high and low affinity agonist binding. In the presence of 10 mM MgCl2, agonists inhibited specific 125IPIN binding with a relatively high potency and low Hill slope, while in the presence of 154 mM NaCl and 300 μM guanosine-5′-triphosphate, agonists inhibited specific 125IPIN binding with a lower potency and an apparent Hill slope closer to 1. To determine which affinity state was relevant to functional receptor stimulation, receptor density was decreased with bromoacetylalprenololmenthane (BAAM). Treatment of membrane preparations with 0.3 μM BAAM produced a 45% decrease in the Bmax for 125IPIN with no change in the apparent KD. Treatment of intact vasa deferentia with increasing concentrations of BAAM resulted in a progressive rightward shift in the dose-response curve to isoprenaline or salbutamol folowed by a decreased maximum response. KA values for isoprenaline and salbutamol in activating the functional β-adrenoceptors were compared with KI values for agonist inhibition of specific 125IPIN binding. The KA values for both agonists were not significantly different from the low affinity KI values, but were significantly different from the high affinity KI values. These data suggest that 1) a homogeneous population of β2-adrenoceptors inhibiting contraction of rat vas deferens can be labelled with 125IPIN, 2) there is a substantial β-adrenoceptor reserve in rat vas deferens; and 3) the initial event in signal transduction by β-adrenoceptors in rat vas deferens is the binding of agonists to the low affinity form of the receptor which is not complexed with the guanine nucleotide binding protein.

Key words

β-Adrenoceptors Vas deferens Spare receptors Occupancy-response relationships 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48–58Google Scholar
  2. Baker SP, Pitha J (1982) Irreversible blockade of beta adrenoceptors and their recovery in the rat heart and lung in vivo. J Pharmacol Exp Ther 220:247–251Google Scholar
  3. Barovsky K, Brooker G (1980) (-)125I-Iodopindolol, a new highly selective radioiodinated beta-adrenergic receptor antagonist; Measurement of beta-receptors on intact rat astrocytoma cells. J Cyclic Nucl Res 6:294–307Google Scholar
  4. Bird SJ, Maquire ME (1978) The agonist-specific effect of magnesium ion on binding by beta-adrenergic receptors in S49 lymphoma cells: Interaction of GTP and magnesium in adenylate cyclase activation. J Biol Chem 253:8826–8834Google Scholar
  5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254Google Scholar
  6. Chang RSL, Lotti VJ (1983) Characterization of β-adrenergic receptors in the rat vas deferens using [3H]-dihydroalprenolol binding. Life Sci 32:2603–2609Google Scholar
  7. Cheng Y-C, Prusoff WH (1973) Relationship between the inhibition constant (K i) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108Google Scholar
  8. DeLean A, Stadel JM, Lefkowitz RJ (1980) A ternary complex explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255:7108–7117Google Scholar
  9. Furchgott RF (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper A, Simmonds B (eds) Advances in drug research, vol 3. Academic Press, London, pp 21–55Google Scholar
  10. Furchgott RF, Jurkiewicz A, Jurkiewicz NH (1973) Antagonism of propranolol to isoproterenol in guinea-pig trachea: Some cautionary findings. In: Usdin E, Snyder SH (eds) Frontiers in catecholamine research. Pergamon Press Inc., Elmsford, NY, pp 295–299Google Scholar
  11. Haga R, Ross EM, Anderson HJ, Gilman AG (1979) Adenylate cyclase permanently uncoupled from hormone receptors in a novel varient of S49 mouse lymphoma cells. Proc Natl Acad Sci USA 74:2016–2020Google Scholar
  12. Hill AV (1910) The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol (Lond) 40:iv-viiGoogle Scholar
  13. Hofstee BHJ (1952) On the evaluation of the constants V m and K m in enzyme reactions. Science 116:329–331Google Scholar
  14. Kent RS, DeLean A, Lefkowitz RJ (1980) A quantitative analysis of beta-adrenergic receptor interactions: Resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17:14–23Google Scholar
  15. Krstew E, Malta E, Raper C (1982) Comparison of guinea pig uterine and rat vas deferens preparations for assessment of beta2-adrenoceptor-mediated activity. J Pharmacol Methods 8:279–289Google Scholar
  16. Lefkowitz RJ, Mullikin D, Caron MG (1976) Regulation of beta adrenergic receptors by guanyl-5′-yl imidodiphosphate and other purine nucleotides. J Biol Chem 251:4684–4692Google Scholar
  17. Lefkowitz RJ, Caron MG, Mickel T, Stadel JM (1982) Mechanisms of hormone receptor-effector coupling: The β-adrenergic receptor and adenylate cyclase. Fed Proc 41:2664–2670Google Scholar
  18. Limbird LE, Gill OM, Lefkowitz RJ (1980) Agonist-promoted coupling of the β-adrenergic receptor with the guanine nucleotide regulatory protein of the adenylate cyclase system. Proc Natl Acad Sci USA 77:775–779Google Scholar
  19. Lotti VJ, Chang RSL, Kling P (1980) 332-1 adrenergic responses in the field-stimulated rat vas deferens. Eur J Pharmacol 68:385–386Google Scholar
  20. Lotti VJ, Kling P, Cerino D (1982) High and low [Gpp(NH)p-sensitive] affinity sites for β2-adrenergic blockers as antagonists of isoproterenol in the field-stimulated rat vas deferens. Eur J Pharmacol 84:161–167Google Scholar
  21. McGrath JC (1978) Adrenergic and non-adrenergic components in the contractile response of the vas deferens to a single indirect stimulus. J Physiol 283:23–39Google Scholar
  22. Mackay D (1978) How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmac 30:312–313Google Scholar
  23. Maguire ME, Van Arsdale PM, Gilman AG (1976) An agonist-specific effect of guanine nucleotides on binding to the beta adrenergic receptor. Mol Pharmacol 12:335–339Google Scholar
  24. Marsh JD, Smith TW (1985) Receptors for β-adrenergic agonists in cultured chick ventricular cells: Relationship between agonist binding and physiologic effect. Mol Pharmacol 27:10–18Google Scholar
  25. Martindale (1977) In: Wade A (ed) The extra pharmacopoeia incorporating squire's companion, 27th edn. The Pharmaceutical Press, London, p 674Google Scholar
  26. Minneman KP, Hedberg A, Molinoff PB (1979a) Comparison of beta adrenergic receptor subtypes in mammalian tissues. J Pharmacol Exp Ther 211:502–508Google Scholar
  27. Minneman KP, Hegstrand LR, Molinoff PB (1979b) Simultaneous determination of beta-1 and beta-2 adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol 16:34–46Google Scholar
  28. Minneman KP, Abel PW (1984) “Spare” alpha1-adrenergic receptors and the potency of agonists in rat vas deferens. Mol Pharmacol 25:56–63Google Scholar
  29. O'Donnell SR, Wanstall JC (1977) The use of functional antagonism to determine whether β-adrenoceptor agonists must have a lower efficacy than isoprenaline to be trachea-atria selective in guinea-pigs. Br J Pharmacol 60:255–262Google Scholar
  30. Pitha J, Zjawiony J, Nasrin N, Lefkowitz RJ, Caron MG (1980) Potent beta adrenergic antagonist possessing chemically reactive group. Life Sci 27:1791–1798Google Scholar
  31. Pitha J, Hughes BA, Kusiak JW, Dax EM, Backer SP (1982) Regeneration of β-adrenergic receptors in senescent rats: A study using an irreversible binding antagonist. Proc Natl Acad Sci USA 79:4424–4427Google Scholar
  32. Ross EM, Gilman AG (1977) Reconstitution of catecholamine-sensitive adenylate cyclase activity: Interaction of solubilized components with receptor-replete membranes. Proc Natl Acad Sci USA 74:3715–3719Google Scholar
  33. Sneddon, P, Westfall DP, Colby J, Fedan JS (1984) A pharmacological investigation of the biphasic nature of the contractile response of rabbit and rat vas deferens to field stimulation. Life Sci 35:1903–1912Google Scholar
  34. Stephenson RP (1956) A modification of receptor theory. Brit J Pharmacol 11:379–393Google Scholar
  35. Terasaki WL, Linden J, Brooker G (1979) Quantitative relationship between beta-adrenergic receptor number and physiologic responses as studied with a long-lasting beta-adrenergic antagonist. Proc Natl Acad Sci USA 76:6401–6405Google Scholar
  36. Venter JC (1979) High efficiency coupling between beta-adrenergic receptors and cardiac contractility: Direct evidence for “spare” beta-adrenergic receptors. Mol Pharmacol 16:429–440Google Scholar
  37. Vohra MM (1979) Evidence for the presence of β2-inhibitory adrenoceptors in the rat vas deferens. Gen Pharmacol 10:221–225Google Scholar
  38. Williams LT, Mullikin D, Lefkowitz RJ (1978) Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors. J Biol Chem 253:2984–2989Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • John Marvin May
    • 1
  • Peter W. Abel
    • 1
  • Kenneth P. Minneman
    • 1
  1. 1.Department of PharmacologyEmory University School of MedicineAtlantaUSA

Personalised recommendations